RxDoctor Payments Data

Michael David, DO

Family Medicine · Martinsville, VANPI 1225568587

Payments from drug & device makers

$12,557in general payments, 2019–2025

Across 850 payments — averaging $14.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Pfizer$952
  • Otsuka America Pharmaceutical, Inc.$869
  • Lilly USA, LLC$754
  • AstraZeneca$482
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$12,526100%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)126$1,871
Novo Nordisk88$1,302
Pfizer104$952
Otsuka America Pharmaceutical, Inc.57$869
Lilly USA, LLC54$754
AstraZeneca28$482
Amgen31$445
Lundbeck LLC26$421
Takeda Pharmaceuticals U.S.A., Inc.23$419
Bayer18$300
GSK17$291
Abbott16$286
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC17$281
Merck18$263
Boehringer Ingelheim16$246
Johnson & Johnson15$227
Currax Pharmaceuticals LLC13$215
Astellas Pharma US Inc13$201
Mylan Specialty L.p.10$190
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)14$176
Dexcom, Inc.10$176
Esperion Therapeutics, Inc.10$152
Ardelyx, Inc.8$148
Phathom Pharmaceuticals, Inc.8$140
Eisai Inc.9$120
Biohaven Pharmaceutical Holding Company Ltd.10$119
Vanda Pharmaceuticals Inc.5$103
Alkermes, Inc.5$101
Nestle Healthcare Nutrition Inc.6$93
Amarin Pharma, Inc.5$85
Novartis5$80
Sanofi-aventis U.S. LLC6$80
Biohaven Pharmaceuticals, Inc.3$74
Aimmune Therapeutics, Inc.4$68
Kowa Pharmaceuticals America, Inc.5$66
Biogen4$65
Sunovion Pharmaceuticals Inc.4$56
Idorsia Pharmaceuticals US Inc3$48
Travere Therapeutics, Inc.2$45
Tandem Diabetes Care, Inc.2$43
Exact Sciences2$41
Axonics, Inc.3$41
Medtronic3$40
Lexicon Pharmaceuticals, Inc.2$35
E.r. Squibb & Sons, L.L.C.2$33
Axsome Therapeutics, Inc.2$33
Impel Pharmaceuticals Inc.2$33
Genentech USA, Inc.2$31
Phadia US Inc.2$30
Corium, LLC2$29
Supernus Pharmaceuticals, Inc.1$25
ARS Pharmaceuticals Operations, Inc.1$23
Teva Pharmaceuticals USA, Inc.1$20
Tactile Systems Technology Inc1$16
Organon1$16
Sanofi Pasteur Inc.1$14
Seqirus USA Inc1$13
Xeris Pharmaceuticals, Inc.1$13
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$11
Metacel Pharmaceuticals LLC1$8

How this compares

$12,557 in reported general payments places this provider in the 95th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$191,611
Medicare patients
577
Services billed
4,884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide62$70,570
RexultiBrexpiprazole41$64,577
FarxigaDapagliflozin Propanediol56$61,276
LinzessLinaclotide75$49,606
EliquisApixaban29$43,659
MounjaroTirzepatide33$37,352
RybelsusSemaglutide31$36,345
XareltoRivaroxaban27$33,994
Soliqua 100-33Insulin Glargine/Lixisenatide19$30,947
ZenpepLipase/Protease/Amylase16$30,162
VraylarCariprazine Hcl18$27,702
MyrbetriqMirabegron35$26,433
KerendiaFinerenone30$25,035
JardianceEmpagliflozin22$25,001
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$21,976

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Levemir$1,302$112,125114 claims
AbbVieLinzess, Vraylar, Synthroid$1,871$79,036115 claims
AstraZenecaFarxiga, Breztri Aerosphere$482$77,68982 claims
Otsuka America Pharmaceutical, Inc.Rexulti$869$64,57741 claims
PfizerEliquis$952$43,65929 claims
Lilly USA, LLCMounjaro, Humalog$754$39,17346 claims
MerckJanuvia, Belsomra$263$39,06361 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$291$37,84277 claims
Johnson & JohnsonXarelto$227$33,99427 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$80$30,94719 claims
Aimmune Therapeutics, Inc.Zenpep$68$30,16216 claims
Astellas Pharma US IncMyrbetriq$201$26,43335 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Martinsville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →